As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.
The Patent Asset Index™ trend of patents for nervous system disorder drugs reveals that the quality of Pfizer’s patents in this field has been dropping steadily since 2005. Their R&D expenditures simply did not pay off.
In contrast, the patent strength of Roche’s portfolio in the same field is rising steadily.